Last reviewed · How we verify

NCT00899184

DNA Changes in Patients With Prostate Cancer

Completed Last updated 19 May 2017
What this trial tests

trial testing polymorphism analysis in Prostate Cancer in 646 participants. Completed in 30 May 2007.

Timeline
23 May 2006
Primary endpoint
30 May 2007
30 May 2007

Quick facts

Lead sponsorECOG-ACRIN Cancer Research Group
StatusCompleted
Study typeOBSERVATIONAL
Enrollment646
Start date23 May 2006
Primary completion30 May 2007
Estimated completion30 May 2007

Drugs / interventions tested

Conditions studied

Sponsor

ECOG-ACRIN Cancer Research Group

Who can join

Adults 18 to 120, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Collecting and storing samples of blood from patients and their brothers with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at changes in DNA in patients and their brothers with prostate cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of polymorphism analysis

Trials testing the same drug.

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

Other ECOG-ACRIN Cancer Research Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00899184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing